Australian oncology company Noxopharm (ASX:NOX) said on Friday that St. Vincent's Hospital Sydney has presented positive interim results from the LuPIN Phase 1/2 clinical trial at the ASCO Genitourinary Cancers (GU) Symposium 2020 held in San Francisco.
St. Vincent's Hospital Sydney is evaluating Noxopharm's lead drug candidate, Veyonda, in combination with 177Lu-PSMA-617, in 56 patients with late-stage metastatic castration-resistant prostate cancer (mCRPC) under the LuPIN study.
All patients had received and failed two prior lines of therapy (chemotherapy and androgen-signaling inhibitors), and most patients (29 of 32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.
Noxopharm CEO Dr Graham Kelly commented that it is remarkable to deliver a meaningful anti-cancer response for at least 50% of patients in late-stage prostate cancer, where the disease involves a number of secondaries in the skeleton, which are a significant and poorly accessible tumour load. A median overall survival of 17.1 months is remarkable for this novel radiosensitizing and immuno-oncology drug.
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial